| Description | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody against phosphatidylserine (PS) with vascular targeting and immunomodulatory properties. It can reactivate anti-tumor immunity to inhibit tumor growth. Bavituximab has anti-cancer activity and is often used in combination with Paclitaxel and Carboplatin to study non-small cell lung cancer. |
| In vitro | Bavituximab通过血清蛋白β2-糖蛋白1(β2GP1)结合至暴露的磷脂酰丝氨酸(PS)分子[1]。Bavituximab通过与PS结合诱导抗体依赖的细胞毒性，导致肿瘤血管的破坏[1]。在10μM索拉非尼作用下诱导暴露PS的情况下，Bavituximab（10 μg/mL; 48 h）能够结合至HUVEC和bEnd.3细胞中的PS[2]。 |
| In vivo | Sorafenib在小鼠肿瘤模型中诱导阴离子磷脂的外露。随后，Bavituximab（100 μg/只小鼠；静脉注射；单剂量；Sorafenib处理后48小时给药）可检测到体内磷脂酰丝氨酸的外露[2]。 |
| Synonyms | Anti-PS MAb 3G4 |
| molecular weight | N/A |
| CAS | 648904-28-3 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. 2. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. |